Maintenance Dose of Tirzepatide
The FDA-approved maintenance doses of tirzepatide are 5 mg, 10 mg, or 15 mg administered subcutaneously once weekly, with the maximum dose being 15 mg weekly. 1
Dosing Algorithm
Initial Titration Phase
- Start at 2.5 mg weekly for the first 4 weeks (this is the starting dose, not a maintenance dose)
- Increase monthly by 2.5 mg increments based on tolerability and response
- The titration schedule allows the body to acclimate and minimizes gastrointestinal side effects 1
Maintenance Dosing Strategy
FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg weekly for both obesity and type 2 diabetes 1. The choice depends on:
- Weight loss goals: Higher doses (15 mg) achieve greater weight reduction (20.9% at 72 weeks) compared to 10 mg (19.5%) or 5 mg (15.0%) 2
- Tolerability: Gastrointestinal side effects increase with higher doses, with discontinuation rates of 6.2% at 15 mg versus 4.3% at 5 mg 3
- Comorbidities: Patients with type 2 diabetes show slightly attenuated weight loss (12.8% at 10 mg, 14.7% at 15 mg) but excellent glycemic control 1
Long-Term Maintenance Considerations
Continued treatment is essential for sustained weight loss. The SURMOUNT-4 trial demonstrated that:
- Continuing tirzepatide at maximum tolerated dose (10 or 15 mg) resulted in additional 5.5% weight loss over 52 weeks
- Switching to placebo led to 14% weight regain
- Overall weight reduction from baseline was 25.3% with continued treatment versus 9.9% with discontinuation 4
Dose reduction to 5 mg may be considered as an alternative to discontinuation, though this results in some weight regain (approximately 6.6% less weight loss compared to maintaining maximum tolerated dose) 5. This strategy may be appropriate for patients experiencing intolerable side effects at higher doses while still providing meaningful benefit over discontinuation.
Clinical Pearls
Optimizing Tolerability
- Slow titration is critical: Monthly dose escalation minimizes gastrointestinal adverse events, which occur primarily during dose escalation 1
- Dietary modifications: Avoid fatty foods, don't eat past fullness, eat smaller portions more frequently 1
- Restart protocol: If treatment is paused or discontinued, patients must restart at 2.5 mg and re-titrate to prevent severe side effects 1
Monitoring Requirements
- Watch for dehydration and renal impairment in patients with vomiting or diarrhea
- Monitor for modest heart rate increases
- Lipase and amylase elevations may occur without pancreatitis
- Increased gallbladder disease risk with any weight loss modality, potentially augmented with GLP-1 receptor agonists 1
Real-World Effectiveness
Recent real-world data suggests that lower maintenance doses (mean 5.32 mg) combined with lifestyle modification can achieve weight loss comparable to higher doses in clinical trials, with 16% weight reduction at 24 weeks 6. However, the landmark SURMOUNT-1 trial achieved similar 16% weight loss only after 72 weeks with higher doses 1, suggesting that individualized dosing with comprehensive lifestyle intervention may accelerate outcomes.